This worry comes from research published in the Endocrine Journal with other drugs in the same group, like semaglutide, that showed there could be an increased risk of things like deep vein thrombosis (DVT) and problems like that
In a Phase 2 obesity trial of retatrutide published in the New England Journal of Medicine in 2023, nausea, diarrhea, vomiting and constipation were cited as the most common adverse events, with higher doses associated with more severe problems
I support individuals and couples in healing by helping them identify inner strengths, develop essential relationship skills, and build self-confidence
The quality of the supplement and the technology used to deliver it are what truly determine the results
And its a byproduct
And so, I think women's medicine is going to probably be the last thing that really gets explored in all of this, right